Resverlogix’s Dr. Ewelina Kulikowski, Senior Vice President, R&D, has written and published an article for the summer 2015 issue of the European Biopharmaceutical Review (EBR) titled,...
Learn More
The practice of modern medicine is based on studies that provide evidence to support whether an approach for treating a disease is beneficial or not. Measuring the effectiveness of a particular...
Learn More
Most clinical trials are conducted to test a medical compound, a device or a diagnostic test in human volunteers and/or patients to add evidence and medical knowledge regarding the treatment of...
Learn More
As discussed in Part 1&2 of the clinical trial series, multiple types of clinical trials exist and they generally happen in sequence, from Phase 1 though Phase 3, evaluating drug...
Learn More
Learn about Resverlogix, epigenetics and apabetalone in under 4 minutes.
Learn More
Resverlogix’s Dr. Ewelina Kulikowski, Senior Vice President, R&D, has written and published an article for the summer 2015 issue of the European Biopharmaceutical Review (EBR) titled, “New Direction.” The article focuses on how BET inhibition has an impact on multiple biologies with the potential to treat a variety of conditions such as cancer, inflammatory, neurodegenerative, metabolic and cardiovascular disorders.
You can read “New Direction,” by Dr. Kulikowski HERE.
